GlassScriptPhysician profile
Raul Heredia
NPI 1366408213
$33,858.86
in general payments reported to CMS, 2019-2025
46 companies · $3,286 in 2025
The $3,286 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,814 · 2020: $11K · 2021: $3,577 · 2022: $4,313 · 2023: $3,450 · 2024: $4,102 · 2025: $3,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,709.57 |
| Education | $128.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $11,909.16 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Janssen Pharmaceuticals, INC | $2,706.89 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $2,258.60 | 2019-2025 | Lifevest |
| Amgen INC. | $2,056.24 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,844.81 | 2019-2025 | |
| Pfizer INC. | $1,821.44 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,126.41 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $1,071.65 | 2019-2025 | Eliquis, Camzyos |
| Esperion Therapeutics, INC. | $992.42 | 2020-2025 | Nexletol |
| Novo Nordisk INC | $955.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $946.34 | 2022-2025 | |
| Amarin Pharma, INC. | $921.20 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $822.99 | 2021-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $726.45 | 2019-2024 | |
| Boston Scientific Corporation | $484.80 | 2019-2025 | Watchman Access System, Bodyguardian, Watchman Flx |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $327.30 | 2019-2025 | Evkeeza |
| Azurity Pharmaceuticals, INC. | $319.10 | 2023-2025 | Edarbi, Edarbi, Edarbyclor |
| Arbor Pharmaceuticals, INC. | $249.35 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $205.69 | 2025 | Onpattro, Amvuttra |
| Lexicon Pharmaceuticals, INC. | $196.38 | 2023-2024 | Inpefa |
| Bridgebio Pharma, INC. | $160.93 | 2025 | Attruby |
| Medicure Pharma INC. | $155.65 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $146.29 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $134.87 | 2025 | Assure Wcd |
| Inari Medical, INC. | $129.28 | 2022 | |
| Edwards Lifesciences Corporation | $122.33 | 2025 | Sapien 3 Ultra Resilia |
| Scpharmaceuticals INC. | $121.14 | 2025 | |
| Amryt Pharma Holdings LTD | $116.06 | 2020-2023 | Juxtapid |
| Abiomed | $115.75 | 2023-2025 | Impella |
| Biotronik INC. | $111.92 | 2019-2023 | Renamic Neo |
| Baxter Healthcare | $109.80 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Akcea Therapeutics, INC. | $107.44 | 2019 | |
| Chiesi USA, INC. | $57.70 | 2025 | Juxtapid |
| Aegerion Pharmaceuticals, INC. | $45.64 | 2019 | |
| Abbott Laboratories | $44.25 | 2024-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Atricure, INC. | $37.93 | 2024 | |
| Lilly USA, LLC | $36.84 | 2020-2021 | |
| Ionis Pharmaceuticals, INC. | $31.93 | 2025 | Tryngolza |
| Glaxosmithkline, LLC. | $23.72 | 2025 | Arexvy, Shingrix |
| Bardy Diagnostics, INC. | $23.47 | 2020 | |
| Philips North America LLC | $19.42 | 2023 | |
| Daiichi Sankyo INC. | $14.22 | 2019 | |
| Heartflow, INC. | $13.56 | 2025 | |
| Preventice Services, LLC | $12.49 | 2021 | |
| Medtronic, INC. | $12.24 | 2021 | |
| Gilead Sciences, INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Heredia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.